Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 3(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00751842Phase 3Terminated

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Role: lead

NCT00723411Phase 3Terminated

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

Role: lead

NCT00456027Phase 2Completed

Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)

Role: lead

NCT00435981Phase 2Completed

Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes

Role: lead

All 4 trials loaded